RHYTHM PHARMACEUTICALS, INC. (RYTM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US76243J1051
RHYTHM PHARMACEUTICALS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 189.76 m USD |
| Gross profit | 170.27 m USD |
| Operating income | -192.02 m USD |
| EBIT | -175.46 m USD |
| Net income | -196.54 m USD |
| Diluted EPS – continuing operations | -3.11 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About RHYTHM PHARMACEUTICALS, INC.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
More stocks
- Zheshang Securities Co Ltd (601878.SS)
- EFG International AG (EFGN.SW)
- Abivax SA (ABVX.PA)
- Abivax SA American Depositary Shares (ABVX)
- Wuhan Jingce Electronic Technology Co Ltd (300567.SZ)
- Mineral Res (MALRY)
- ExlService Holdings, Inc. (EXLS)
- Ingredion Inc (INGR)
- Sailun Jinyu Group Co Ltd (601058.SS)
- GPT Group (GPT.AX)
- FirstService Corp (FSV.TO)
- Castellum AB (CAST.ST)
Not investment advice. All data without warranty, price as of 19.10.2026. Details in the risk notice.